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ABSTRACT 
 
 
Our research focuses on the development of kappa opioid receptor (KOR) 
antagonists. KOR antagonists have a variety of possible therapeutic applications; 
these compounds have shown anxiolytic activity, anti-depressive activity, and have 
potential uses in the treatment of opioid and cocaine addiction. Dynorphin A (Dyn A) 
is an endogenous agonist at KOR. Dyn A has been used as a lead for the development 
of KOR antagonists including arodyn, an acetylated Dyn A analog identified in our 
laboratory. Arodyn is a potent and selective KOR antagonist that has shown promise 
in the treatment of stress-induced relapse of cocaine seeking behavior. However, 
arodyn is rapidly metabolized in rat brain homogenate and slices.  The objective of 
this research was to synthesize arodyn analogs with greater metabolic stability and to 
test these analogs in metabolism studies. Previous research in our laboratory had 
identified the sites of cleavage in arodyn and these sites were targeted for 
modification.  Analogs with extended sequences, N-methylarginine replacements and 
reduced amide bond stabilizations were synthesized. In metabolism studies in 
washings from rat brain slices, several analogs were identified that showed increased 
stability over arodyn. 
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ABBREVIATIONS 
 
 Abbreviations used for amino acids follow the rules of the IUPAC-IUB Joint 
Commission of Biochemical Nomenclature in Eur. J. Biochem. 1984, 138, 9-37. 
Amino Acids are in the L-configuration except where indicated otherwise. Additional 
abbreviations used in this thesis are as follows: 
AC: adenylyl cyclase; 
Boc: tert-butyloxycarbonyl; 
cAMP: cyclic adenosine monophosphate; 
CHO: Chinese hamster ovary; 
DCM: dichloromethane; 
DIEA: N,N-diisopropylethylamine; 
DMF: N,N-dimethylformamide; 
Dyn A: dynorphin A; 
ESI-MS: electrospray ionization mass spectrometry; 
Fmoc: 9-fluorenylmethoxycarbonyl; 
GDP: guanosine 5’-diphosphate; 
GNTI: guanidinium naltrindole; 
GPI: guinea pig ileum; 
GPCR: G-protein coupled receptor; 
GTP: guanosine-5'-triphosphate; 
GTPγS: guanosine-5'-(3-thiotriphosphate); 
HOBt: 1-hydroxybenzotriazole; 
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HPLC: high-performance liquid chromatography; 
i.c.v.: intracerebroventricular; 
i.p.: intraperitoneal; 
i.v.: intravenous; 
LH-RH: lutenizing hormone-releasing hormone; 
Mtr: 4-Methoxy-2,3,6-trimethylbenzenesulfonyl; 
norBNI: nor-binaltorphimine; 
NMR: nuclear magnetic resonance; 
ORL-1: opioid-receptor like-1; 
PAL: peptide amide linker; 
PEG: poly(ethylene glycol); 
PS: polystyrene; 
PyBOP:benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate;  
s.c.: subcutaneous; 
SAR: structure-activity relationship; 
SEM: standard error of mean; 
SPPS: solid-phase peptide synthesis; 
TFA: trifluoroacetic acid; 
Tic: 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; 
TIPS: triisopropylsilane; 
TLC: thin layer chromatography. 
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The objective of this research was to synthesize and evaluate the metabolism of 
new analogs of peptide kappa opioid receptor (KOR) antagonists.  
KOR antagonists can be used for the study of KOR receptor function. There is 
also interest in the development of KOR antagonists as clinical agents. KOR 
antagonists have been shown to have antidepressant activity in the forced swim test in 
rats.1 KOR antagonists can decrease the withdrawal signs in opioid addicted subjects, 
and therefore also have potential application in the treatment of opioid addiction.2, 3 
KOR antagonists have shown promise as treatments for cocaine dependence by 
preventing stress related relapse.4, 5 Studies on mice showed that KOR antagonists can 
prevent stress-induced relapse of cocaine seeking behavior.4, 5 
Non-peptide KOR antagonists such as norbinaltorphimine (norBNI) and (3R)-
7-Hydroxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-
piperidinyl]methyl]-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinoline-carboxamide 
(JDTic) show extremely long duration of action.6 NorBNI, injected systemically, 
maintained kappa opioid receptor (KOR) antagonist activity for up to 4 weeks in 
mice.7 JDTic has kappa opioid antagonist effects following oral (p.o.) and 
subcutaneous (s.c.) administration for up to 28 days in rats.8 The therapeutic utility of 
drugs displaying such a long duration of action may be limited because potential side-
effects or toxicities could also be long lasting.   
The dynorphins are endogenous ligands for KOR, and these have been used as 
lead compounds for the development of KOR selective ligands. Peptides generally 
have high selectivity and low toxicity9, though they are often metabolized more 
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quickly in vivo than small molecule ligands as a result of peptidase activity.  Because 
of this, peptides are generally not expected to exhibit as long-lasting activity as small 
molecules. Furthermore, peptides and small molecules have been shown to bind to 
different regions of KOR.10 Thus, peptides and small molecules may provide different 
information about this receptor, and peptides could have somewhat different activity 
than small molecules at KOR.  Structural modifications to dynorphin A (Dyn A) have 
led to the development of novel KOR agonist and antagonist ligands.  
Arodyn (Ac[Phe1,2,3,Arg4,D-Ala8]dynorphin A-(1-11)NH2) is a selective  and 
potent KOR receptor antagonist that was developed from a 1-11 fragment of the 
endogenous KOR agonist Dyn  A11 The design and synthesis of Dyn A analogs has 
been a focus of the Aldrich laboratory research for several years.  Replacement of the 
“message” sequence of [D-Ala8]Dyn A(1-11)NH2 with a µ  opioid receptor antagonist 
followed by structural modifications using a combinatorial library resulted in the 
discovery of arodyn.11 A comparison of dynorphin A and arodyn structures is shown 
in Figure 1-1.Arodyn exhibits high KOR selectivity and antagonist potency.11 
 
Ac-Phe-Phe-Phe-Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-NH2
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile -Arg-Pro-Lys-Leu
Dynorphin A(1-11)
Arodyn  
Figure 1-1: Comparison of dynorphin A(1-11) and arodyn structures. 
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Arodyn was evaluated in a tail withdrawal assay and a cocaine conditioned 
place preference assay.4 Several small molecule KOR antagonists and arodyn were 
tested in the tail withdrawal assay against the KOR agonist U50,488.  These assays 
showed that withdrawal latencies were reduced for 1-3 days for arodyn pretreated 
mice compared to saline-pretreated mice. The small molecule KOR antagonists 
norBNI and JDTic had much longer lasting antagonist activity; tail withdrawal 
latencies were reduced for at least 7 days.4 
 A conditioned place preference assay was carried out for arodyn.4 Mice were 
first treated with cocaine, associated with only one compartment in the apparatus. 
The mice then showed a preference for the cocaine-associated compartment. Cocaine 
was removed for three weeks and the place preference became extinct.  Following 
extinction, mice were subjected to a forced swim-stress protocol. Those mice 
pretreated with arodyn did not relapse into drug seeking behavior, while mice in the 
control group exhibited reinstatement of the cocaine place preference.4  
Metabolic studies in the Aldrich laboratory showed arodyn to be rapidly 
metabolized in rat blood or brain homogenate, with complete disappearance of the 
parent peptide in under 15 minutes.12 These studies identified potential sites of 
metabolism. 
Arodyn has shown promise in in vivo assays in preventing reinstatement of 
cocaine abuse. Its short half-life, though, limits its potential as a therapeutically 
useful drug. More metabolically stable analogs could lead to the development of a 
drug for the treatment of cocaine addiction. In addition, stable analogs may provide 
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insight into whether a longer lasting metabolite is responsible for arodyn’s long-
lasting activity. 
1.1 Objectives and Hypotheses 
By modification of potential cleavage sites we can increase the metabolic 
stability of arodyn. The objective of the research presented in this thesis is to identify 
the modifications to arodyn that increase the stability of the peptide. In addition, the 
selectivity and potency of arodyn should be maintained in the new analogs.   
Previous investigation into the structure-activity relationships for arodyn13 
identified the arginine residues as the most important for binding – replacement of 
these residues with alanine resulted in the largest decreases in affinity for KOR.  
Thus, these side chains should be retained in new analogs.  
The potential cleavage sites identified in an earlier metabolism study12 are clear 
targets for stabilization. Since these potential cleavage sites were next to arginines it 
is necessary to make modifications that stabilize the peptide bond while maintaining 
the arginine side chain functionality. Thus, backbone modifications (N-
methylarginine substitutions and reduction of the peptide bond) have been chosen, in 
addition to C-terminal extended analogs. 
Metabolism studies using washings from rat brain slices were performed to 
assess which analogs, if any, had increased stability over arodyn. 
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1.2 Research 
1.2.1 Design and Synthesis of Arodyn Analogs 
A series of four reduced amide bond analogs, a series four of N-
methylarginine analogs and two extended analogs were designed and synthesized. In 
to determine which modifications are most effective at slowing metabolism, only one 
modification was made per analog. 
 Substitution of each arginine with an N-methylarginine maintains the side-
chain functionality while stabilizing the peptide bond to peptidase metabolism. The 
more sterically hindered N-methyl peptide bond should hinder peptidase cleavage at 
this site.14 Each arginine was replaced in separate analogs.  
 Reduced amide bonds replace the peptide bonds with amine functionalities. 
This, like the α-N-Me-Arg replacement, maintains the original side chains. The 
cleavage at this site should be completely blocked, as there is no longer a peptide 
bond for a peptidase to attack.14 The reduced amide bond was introduced at the N-
terminus of each arginine residue in separate analogs.   
 Extended analogs are attractive because they are simple modifications which 
may change the rate of breakdown by peptidases.  It has been observed that rates of 
peptidase breakdown of dynorphins vary by the size of the dynorphin fragment.15 
Thus, it is possible that simply extending the peptide sequence of arodyn may alter 
metabolism. 
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Since extending a peptide sequence involves standardized coupling and 
deblocking procedures to add each additional amino acid. These modifications are 
easily implemented. 
1.2.2 Metabolism Studies 
Metabolism studies were done in order to identify the modifications that most 
hindered metabolism.  Seven analogs were tested in the initial metabolism studies. 
The metabolism of these analogs was followed for 60 minutes and analyzed using 
MALDI-MS (matrix assisted laser desorption/ionization mass spectrometry). Several 
analogs were identified that were more stable than arodyn (lasting up to 30 or even 60 
minutes in these studies, compared to less than 10 minutes for arodyn).  
1.3 Significance 
There are nearly 5.3 million cocaine users in the U.S.16 Currently there are no 
medications available for the treatment of cocaine addiction.17 KOR antagonists have 
shown potential as therapeutics for stress-induced relapse of cocaine addiction. Stress 
can enhance the rewarding properties of drugs of abuse and has been shown to induce 
relapse leading to drug abuse and to potentiate drug-seeking behavior.18 KOR 
antagonists have been shown to reduce aversive behavior in mouse stress tests.19 
Arodyn showed potential as a cocaine addiction treatment in conditioned 
place preference tests in mice. However, arodyn is rapidly degraded in rat whole 
blood and brain homogenate due to endopeptidase metabolism, with complete 
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disappearance of the parent peptide in under 15 minutes.12 In order to produce a 
therapeutically useful drug, the stability of this peptide would have to be increased.  
New analogs could lead to the development of stable compounds and a 
therapeutically useful drug.    Development of stable analogs might also give insight 
into whether arodyn's long-lasting activity is due to an active metabolite. 
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2.1 Opioid Receptors 
 
Opium, derived from the latex of the opium poppy, Papaver somniferum, has 
been used as a medicinal agent for centuries.1 The major active ingredient, morphine, 
was first isolated in 1805.2 Modifications of the structure of morphine have produced 
other pharmacologically active compounds, such as heroin. However, it was not until 
the 20th century that opioid receptors were discovered to be the site of action of these 
compounds.3 
2.1.1 Classification and Endogenous Ligands 
 
Based on behavioral studies of chronic spinal dogs, Martin4, 5 posited the 
existence of three types of opioid receptors. These receptors were labeled according 
the drugs used in the study - mu (µ) for morphine and kappa (κ) for ketacyclazocine. 
A new type of opioid receptors, delta (δ) opioid receptors, was proposed in 1977 by 
Kosterlitz and coworkers based on studies with enkephalins in the mouse vas deferens 
(MVD).6 The µ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid 
receptor (DOR) have all been cloned.7-9 In addition, a new type of opioid-like 
receptor was discovered and cloned.10 This receptor does not bind classical opioid 
agonists or antagonists with high affinity and, therefore, has been called the opioid-
receptor like (ORL-1) receptor. 
In the 1970s, Hughes et al.11 isolated two pentapeptides from mammalian 
brain tissue - Leu-enkephalin and Met-enkephalin. These peptides showed morphine-
like activity and were shown to be opioid agonists in the guinea pig ileum (GPI) and 
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MVD assays. The name “enkephalin” was given to these compounds after kaphale - 
the Greek work for “from the head”. Later, other endogenous opioid peptides were 
discovered: β-endorphin,12 the dynorphins13 and, recently, the endomorphins.14 Table 
2-1 summarizes the mammalian endogenous ligands for MOR, KOR and DOR along 
with their receptor selectivities. 
Endogenous ligands for KOR arise from the precursor protein prodynorphin. 
When prodynorphin is cleaved during processing, multiple active peptides are 
released: dynorphin A, dynorphin B, α− and β-neoendorphin.15  
Table 2-1: Endogenous Opioid Ligands 
Peptide Amino Acid Sequence Selectivity1 
Leu-enkephalin  Y-G-G-F-L δ>µ>>κ 
Met-enkephalin  Y-G-G-F-M δ>µ>>κ 
β-Endorphin  Y-G-G-F-M-T-S-E-K-S-Q-T-P-L-V-
T-L-F-K-N-A-I-I-K-N-Y-A-Y-K-G-E 
µ≅δ 
Dynorphin A  Y-G-G-F-L-R-R-I-R-P-K-L-K-W-D-
N-Q 
κ>µ>δ 
Dynorphin B  Y-G-G-F-L-R-R-N-F-K-V-V-T κ>µ>δ 
α-Neoendorphin  Y-G-G-F-L-R-K-Y-P-K κ>δ,µ 
β-Neoendorphin  Y-G-G-F-L-R-K-Y-P κ>δ,µ 
Endomorphin-1  Y-P-W-F-NH2 µ>>κ, δ 
Endomorphin-2  Y-P-F-F-NH2 µ>>κ, δ 
Nociceptin/orphanin 
FQ  
F-G-G-F-T-G-A-R-K-S-A-R-K-L-A-
N-Q 
ORL1 
 
2.1.2 Pharmacology 
 
Opioid receptors are part of the rhodopsin subclass of G-protein coupled 
receptors (GPCRs). GPCRs have characteristic seven helical transmembrane regions, 
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an extracellular N-terminus, and an intracellular C-terminus.16 A diagram of a GPCR  
is shown in Figure 2-1. 
 
 
Figure 2-1: G-protein coupled receptor(from berkely.edu17) 
 
Opioid receptors are coupled to the Gi/Go family of G-proteins at their 
intracellular domain. All G-proteins are composed of α, β and γ subunits. After 
agonist binding the receptor changes conformation which promotes the release of 
guanosine 5'-diphophate (GDP) from the α subunit. The α subunit then binds 
gunaosine 5'-triphophate (GTP). The G-protein then dissociates from the receptor, 
and the α subunit is separated from the βγ dimer. The α subunit and βγ dimer can 
then associate with other molecules inside the cell to modulate biological functions.18, 
19 When GTP is hydrolyzed to GDP by the α subunit, the G-protein can then 
reassemble and reassociate with the receptor.  
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Gi alpha (or Go alpha) is a subunit that inhibits the production of cAMP from 
ATP, which results in decreased activity of cAMP-dependent protein kinase.  This 
results in lowered neurotransmitter release in neurons.20 
2.1.3 Kappa Opioid Receptors 
 
 Drugs affecting the µ opioid receptor (such as morphine and heroin) are 
associated with analgesia, but also with the side effects respiratory depression, 
constipation, euphoria and physical dependence. The δ opioid receptor can also 
mediate analgesic effects, but can have the side-effect of seizures.21  
KOR agonists have been shown to be analgesics without the µ-associated 
adverse effects;22 The effectiveness of KOR agonists depends on the pain type. For 
some types of pain (e.g. thermal) KOR agonists are not as effective as MOR 
agonists.1 Recently, studies have established that KOR agonists can produce analgesia 
peripherally both in somatic and visceral pain models, particularly in certain 
conditions involving inflammation.23 However, KOR agonists have been reported to 
cause side effects such as dysphoria.24, 25 Recently, some KOR agonists were reported 
to have the potential to be used as peripheral analgesics without central nervous 
system (CNS) side effects,26 and, therefore, there has been an interest in developing 
peripheral KOR agonists1 for the treatment of pain.  
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KOR agonism has a wide variety of effects beyond analgesia. Activation of 
KOR antagonizes many of the effects of MOR.27 Also, kappa agonists may be 
neuroprotective against hypoxia/ischemia.28 KOR agonists, especially the 
arylacetamide series of agonists, have been shown to have anticonvulsant and 
neuroprotective properties, and may have potential to treat epilepsy, stroke, or trauma 
resulting from brain or spinal cord injury.29 KOR agonists have also been shown to 
cause the down-regulation of HIV expression in microglia30 and CD4+ 
lymphocytes.31 
KOR antagonists can be used for the study of KOR function. Currently, there 
is also increased interest in the development of KOR antagonists as clinical agents. 
KOR antagonists have been shown to have antidepressant activity in the forced swim 
test in rats32 and anti-anxiety activity in rats. 33 KOR antagonists can decrease the 
withdrawal signs in opioid addicted subjects, and therefore also have potential 
application in the treatment of opioid addiction.34, 35 
In addition, both kappa agonists and antagonists have shown potential as 
treatments for cocaine dependence, but by different mechanisms as will be described 
below.  
2.1.4 Nonpeptide KOR Antagonists 
 
Nor-binaltorphimine (BNI) (Figure 2-2) was an early small molecule KOR 
antagonist reported in 1987.36 NorBNI has high potency and selectivity for KOR. 
Structure-activity relationship (SAR) studies of the δ receptor antagonist naltrindole 
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led to the discovery of a highly selective κ antagonist, 5'-guanidinium naltrindole 
(GNTI, Figure 2-3).37 
The small molecule KOR antagonist JDTic (Figure 2-4) was reported in 2001 
by Thomas et al.38 It was later shown to suppress stress induced-reinstatement of 
cocaine-seeking behavior in rats.39  
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Figure 2-2: NorBNI 
 
 
Figure 2-3: GNTI 
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Figure 2-4: JDTic 
 
2.1.5 Cocaine Abuse  
 
Cocaine is a psychostimulant found in the leaves of the coca plant. There are 
nearly 5.3 million cocaine users in the U.S.40 Between 5-6% of new users become 
dependent within two years of their first use of cocaine.40 Given roughly 1.2 million 
new users in 2001, an estimated $86,400,000 per year would be required to treat just 
new cases.40 Cocaine use can result in severe paranoia, mood disturbances, 
hallucinations, seizures and fatal overdose.41 
In addition to the private toll of addiction, there are public costs in terms of 
public health and law enforcement. Thirty-seven percent of state law enforcement 
agencies in the United States cited cocaine as the greatest drug threat, according to 
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the 2003 National Drug Threat Survey.41 Currently there are no medications available 
for the treatment of cocaine addiction.42  
Cocaine acts by blocking dopamine uptake by the dopamine transporter 
(DAT), effectively increasing dopamine signaling, which is thought to be associated 
with the rewarding effects of the drug.43, 44 Thus, some medications under 
development act as “agonist substitutes” for cocaine and target dopamine receptors or 
DAT.45, 46 However, DAT gene knockout mice still self-adminster cocaine, and 
studies implicate serotonin and norepinephrine transporters in the pharmacological 
effects of psychostimulants.47 Therefore, disruption of dopamine or DAT activity may 
not be sufficient to treat cocaine addiction.   
Thus, the kappa opioid receptor presents a novel target for the treatment of 
cocaine addiction. 
2.1.6 Drug Abuse Treatments Targeting KOR 
 
Both agonists and antagonists of KOR have shown promise in treating cocaine 
dependence. They appear to work via different mechanisms, making each possible 
agents for the treatment of addiction.  
2.1.6.1 KOR Agonists 
 
The endogenous KOR ligands,  the dynorphins, have been found to modulate 
both pain and addiction.48 Kappa opioid receptors are located in proximity to 
dopamine receptors in the nucleus accumbens which may be why KOR agonists 
affects dopamine signaling.49 KOR activation is known to inhibit dopamine (DA) 
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release50 and is connected to cocaine aversion.51 Agonism of KOR also affects DAT 
uptake of DA.52 Administration of E-2078, a dynorphin A analog, was shown to 
decrease DA release.53 When dynorphin A is infused into a mouse brain, it suppresses 
cocaine-induced release of DA and reward (as measured by a condition place 
preference assay).54 Further evidence that kappa agonism blocks cocaine’s rewarding 
effects is that the kappa agonists U50,488 and spiradoline produce dose-related acute 
decreases in cocaine self-administration in rats.55 
However, while KOR agonists can suppress cocaine reward and self-
administration over short courses of treatment, repeated treatment actually increases 
cocaine craving. Repeated treatment results in a lowering of DAT activity (thus 
increasing dopamine signaling) without changing the total levels of expression of 
DAT protein.41 Stress and depression are common factors in relapse of cocaine abuse 
and KOR agonism is involved in the stress response  (specifically mediating the 
dysphoric feelings associated with stress56). Conversely, KOR antagonists exhibit 
antidepressant activity.32  
 Thus, while KOR agonists may be suitable for short-term suppression of 
cocaine reward and craving, they do not appear suitable for longer-term prevention of 
relapse. 
2.1.6.2 Kappa Antagonists 
 
KOR antagonists have also shown potential for treatment of addiction, 
particularly in prevention of stress-induced relapse of cocaine-seeking behavior.37, 39, 
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57 This may be mediated by an entirely different mechanism than KOR agonists. KOR 
antagonists prevent the dysphoric feelings associated with stress.56 
The non-peptide KOR anatagonists, GNTI, norBNI and JDTic all have 
unusually long-lasting pharmacological effects. In mice, KOR antagonism lasts for up 
to 3 weeks after a single injection of norBNI.58 Antagonism due to JDTic is similarly 
long, lasting at least 10-14 days.59, 60 The mechanism for these effects is not entirely 
clear, although theories have been proposed.  Bruchas et al. found that norBNI did 
not downregulate κ opioid receptors and, as expected, it did not bind to the receptor 
covalently. They proposed that activation of c-Jun N-terminal kinase (JNK) 
phosphorylation is involved, although both the KOR antagonist norBNI and KOR 
agonist U50,488 produced JNK activation.59 Thus, JNK activation alone is not 
sufficient to produce long-lasting antagonism.  
In results by Aldrich and McLaughlin,61 binding assays following treatment 
with arodyn or the small molecule antagonists, either in vitro or in vivo, indicated that 
arodyn did not affect receptor density, while norBNI and JDTic lowered receptor 
density. They propose that long-lasting activity of these small molecules may be 
attributed to a depot effect. 
The long-lasting pharmacological effects of the small molecule selective KOR 
antagonists pose concerns because of potential toxicity issues. If the antagonistic 
effects last for several weeks, so might any toxic effects.  Thus, there is interest in 
developing new antagonists that might not have as long-lasting activity. 
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2.2 Peptides as Therapeutics 
 
Peptides often have high activity, high specificity and low toxicity.62 Eli 
Lilly's synthetic parathyroid hormone has a dosage of only 20 micrograms a day.62 
Peptides have been marketed as successful drug. The synthetic hormone insulin lispro 
brings in $1.1 billion a year for Eli Lilly.62 Daptomycin is a lipopeptide antibiotic, 
and ziconotide, a synthetic version of a sea snail venom used to treat chronic pain, is 
also on the market.62 
There are several potential drawbacks to peptides as drugs, including low oral 
availability, so another route of administration (primarily injection) is often used. In 
addition, peptides are often metabolically unstable and are rapidly cleared from the 
body, have difficulty crossing membranes, and can be expensive to synthesize. 
However, many of these drawbacks can be overcome. Slow release injectable 
formulations and nasal sprays of current peptide drugs are on the market (injectable 
leuprolide formulations can last for months). Metabolic instability can be addressed 
through structural modifications to slow peptidase cleavage.  The ability to cross 
membranes can also be improved; for example, the dynorphin A analog E-2078 
(NMeTyr-Gly-Gly-Phe-Leu-Arg-NMeArg-D-Leu-NHC2H5) was found to cross the 
blood brain barrier (BBB), and further in-depth studies reported that this peptide was 
transported by absorptive-mediated endocytosis.63 Finally, although peptides are 
costly on weight basis to synthesize, they can also have high potencies and thus less is 
needed per dose. 
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2.3 Discovery of Arodyn 
2.3.1 Dynorphins 
 
 Dynorphin A (Dyn A) is the most studied endogenous ligand for the κ opioid 
receptor. Dyn A (Figure 2-5) was first isolated from porcine pituitary gland.64 Dyn A 
is implicated in motor dysfunction, cardiovascular effects, inflammatory response, 
feeding behaviors, immunomodulation and stress,56, 65, 66 although some of these 
effects are not mediated by opioid receptors.  Dyn A(1-13) has been shown to 
suppress opiate withdrawal and tolerance when administered to morphine-dependent 
mice.67 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys...
Message Address  
Figure 2-5: Dynorphin A 
 The structure-activity relationships of dynorphin A have been explored.1, 68, 69 
The N-terminal sequence of this peptide is Tyr-Gly-Gly-Phe, the same as for most 
mammalian opioid peptides; the C-terminal sequence is different from other 
endogenous mammalian opioid peptides. Goldstein and coworkers proposed the 
“message-address” hypothesis for Dyn A70 (an extension of the original  concept 
posited by Schwyzer71), where the N-terminal sequence is the “message” that is 
responsible for activation of opioid receptors, while the C-terminal sequence is the 
“address” that is responsible for KOR affinity.70 Thus, the Tyr-Gly-Gly-Phe sequence 
is general for the entire opioid family, while the C-terminal sequences of endogenous 
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peptides vary according to the receptor type for which the peptide preferentially 
interacts. 
Dynorphin A has been used as a starting point for the development of KOR 
antagonists. These include dynantin, where the N-terminal tyrosine was replaced with 
a des-amino tyrosine analog. Dynantin has high affinity, selectivity and potency at 
KOR.72 Another analog, Pro3Dyn A(1-11)NH2 has very high selectivity, but the 
antagonist potency is weak.73 
Our laboratory has developed several promising Dyn A analogs that function 
as KOR antagonists. The cyclic analog [Nα-benzylTyr1,cyclo(D-Asp5,Dap8)]-
dynorphin A(1-11)NH2 exhibits nanomolar affinity and high selectivity for KOR.74 
Chimeric analogs have been developed which combine the “address” 
sequence of Dyn A with a small peptide with known antagonist activity.  In our 
laboratory, a chimeric Dyn A(1-11) analog, JVA901, was developed.75 The 
pentapeptide Boc-Tyr-Lys-Trp-Trp-NH2 was known to be a selective but weak KOR 
antagonist.75 An N-terminal acetylated tetrapeptide derivative was combined with the 
“address” sequence (resides 5-11) of [D-Ala8]Dyn A(1-11)NH2 to produce JVA901. 
This peptide showed improved KOR affinity and selectivity compared to the starting 
tetrapeptide and demonstrated antagonist activity against Dyn A (1-13)NH2 in the 
adenylyl cyclase assay.75 
Replacement of the “message” sequence of [D-Ala8]DynA(1-11)NH2 with a MOR 
antagonist (Ac-Arg-Phe-Met-Trp-Met-Arg-NH2) followed by structural modifications 
using a combinatorial library resulted in the discovery of arodyn (Figure 2-6), a 
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potent and selective KOR  antagonist.76 Arodyn ([Ac-Phe1,2,3,Arg4,D-Ala8]Dyn A-(1-
11)NH2), exhibits high KOR affinity and selectivity (Ki(KOR) = 10nM, Ki ratio 
(KOR/MOR/DOR) = 1/174/538) as well as potent antagonist activity (KB = 2.0 nM in 
the adenylyl cyclase assay using cloned κ opioid receptors).76 
 
Ac-Phe-Phe-Phe-Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-NH2
 
Figure 2-6: Arodyn 
 
2.3.2 Tail Withdrawal Assay 
 
Arodyn was compared to the small molecule KOR antagonists norBNI and 
JDTic in an antinociceptive assay.57 Mice were pretreated with a KOR antagonist or 
the control saline, then later given the KOR agonist U50,488 and subjected to the 55 
ºC warm water tail wihtdrawal test. Mice pretreated with arodyn (i.c.v.) had 
significantly shorter tail withdrawal latencies than mice pretreated with saline for up 
to 3 days after the arodyn dosage (Figure 2-7, the decrease in tail withdrawal latency 
at 7 days was not statistically significant). Both norBNI and JDTic exhibited 
extremely long-lasting activity in this assay; animals pretreated with these compounds 
had significantly lowered tail withdrawal latencies for at least 7 days after 
pretreatment. Thus, while arodyn has somewhat long-lasting activity (1-3 days), it is 
not as extremely long lasting as norBNI or JDTic. 
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Figure 2-7: Mouse latency to tail withdrawal from 55ºC water: time course of 
KOR antagonism after a single pretreatment with the drugs listed. * = sig. 
different (p < 0.05) from saline control57 
 
2.3.3 Conditioned Place Preference 
 
Arodyn showed promise in preventing stress-related relapse of cocaine 
seeking behavior in mice (Figure 2-8).57 Mice were first given cocaine, which was 
distributed from one compartment. After establishing a conditioned place preference 
(CPP) for the cocaine-associated compartment, the cocaine was then removed and the 
CPP was extinguished after 3 weeks. Mice pretreated with arodyn and then subjected 
to forced swim stress did not show reinstatement of CPP, while the control group did 
exhibit reinstatement of CPP after the stressor. Reinstatement of CPP could also be 
produced with a single dose of cocaine after extinction. This effect is not blocked by 
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arodyn or other KOR antagonists.57 This supports a role of KOR in stress-induced 
relapse of cocaine seeking behavior. 
The tail withdrawal assay shows that arodyn is a KOR antagonist in vivo and 
the CPP study demonstrated that a peptide KOR antagonist such as  arodyn may have 
potential in the treatment of stress-induced relapse of cocaine abuse. 
 
 
 
Figure 2-8: Arodyn (0.3 nmol i.c.v.) blocks stress-induced, but not cocaine 
primed, reinstatement of cocaine CPP *, †, ζ =  sig. different (p < 0.05) from 
preconditioning, postconditioning, and matched vehicle control animals. 57 
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2.3.4 Arodyn SAR 
 
The SAR of arodyn was previously investigated;77 results are shown in Figure 
2-9. The SAR of arodyn is unusual in that no particular residues stand out as critical 
(substitution of some arginines with alanine results in a > 5 fold decrease of affinity 
for KOR). The SAR also was interesting when compared with that of Dyn A(1-11).  
Substitution of phenylalanine in positions 1–3 of arodyn causes only a 4-fold decrease 
in affinity for KOR. Substitution of aromatic residues in positions 1 and 4 of Dyn 
A(1-13) results in very large decreases in opioid receptor affinity (greater than 500 
and 270-fold decreases, respectively).78 Also, substitution of Tyr1 in Dyn A(1–
11)NH2 with Phe results in a 21-fold loss in binding affinity for KOR, 79while 
substituting Tyr in place of Phe in position 1 of arodyn results in the much smaller 7-
fold decrease in affinity for κ opioid receptors.77  
 
Figure 2-9: Arodyn SAR77 
 
2.4 Metabolism 
 
Metabolism plays a large role in the pharmacokinetic and pharmaceutical 
properties of drugs. Most unmodified peptides are rapidly degraded in plasma, which 
limits their application as therapeutics. In blood, a variety of peptidases (endo- and 
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exopeptidases) are present that cleave peptides efficiently.80   Exopeptidases 
(aminopeptidases, carboxypeptidases, peptidyl di- and tripeptidases) act on the free 
termini (amino or carboxy) of a peptide chain. Endopeptidases act preferentially in 
the inner region of a peptide chain away from the amino and carboxy termini.  
2.4.1 Dynorphin A Metabolism 
 
The metabolism of dynorphin analogs has been analyzed previously by LC-
MS (liquid-chromatography mass spectrometry) in brain microdialysis81,82 and 
plasma samples.83 Both ESI84,85,81 and MALDI (matrix-assisted laser desorption 
ionization) based MS methods82,83 have been utilized for the investigation of the 
metabolism of dynorphin peptides in a variety of biological matrices.  
In rat plasma, dynorphin A fragments undergo rapid metabolism (t1/2< 5 min) 
by plasma enzymes.86 Dynorphin A is cleaved by membrane bound amino- and 
carboxypeptidases as well as other endogenous enzymes in the central nervous 
system (CNS).82 Dyn A(1-13) can release shorter enkephalin sequences after 
metabolism.86, 87  
The metabolic fragments observed from Dyn A breakdown depends both on 
the type of tissue as well as the length of the starting fragment (i.e. Dyn A(1-13) can 
be metabolized differently than Dyn A(1-11).80 
Several enzymes involved in the break down of dynorphin have been 
identified. Thimet-oligopeptidase (EC 3.4.24.15) is a metallo-endopeptidase that has 
been reported to be involved in the breakdown of a variety of peptides at the Leu-Arg 
bond, including the dynorphins.88 Several endopeptidases that cleave dynorphin A at 
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monobasic and dibasic sites have been investigated.82, 89-93 These enzymes include 
dynorphin  A converting enzyme and dynorphin A(1-17) processing enzyme. A 
summary of these enzymes and their cleavage sites is in Table 2-2. 
Table 2-2: Endopeptidase biotransformation of dynorphin A, adapted from 
Reed et al (2003)82 
Primary Fragments 
Observed 
Cleavage 
Sites 
Enzyme Reference 
Dyn A(1-5), Dyn A(6-17) Leu5-Arg6 
Dyn A(1-6), Dyn A(7-17) Arg6-Arg7 
Dyn A(1-7), Dyn A(8-17) Arg7-Ile8 
Dynorphin A 
Converting Enzyme 
(EC 3.4.22) 
Silberring et al 
(1992) 93 
Dyn A (1-9) Arg9-Pro10 Proprotein Convertase 
2 (EC 3.4.21) 
Day et al (1998)94 
Dyn A(1-6), Dyn A(7-17) Arg6-Arg7 Dynorphin A 
Processing Enzyme 
(EC 3.4.24) 
Berman et al 
(1999)89 
Dyn A(1-7), Dyn A(8-17) Arg7-Ile8 unidentified Reed et al (2003)82 
  
2.4.2 Arodyn Metabolism 
Arodyn is acetylated at the N-terminus and amidated at the C-terminus, and 
thus should be stable to exopeptidase metabolism However, arodyn is susceptible to 
rapid metabolism by endopeptidases present in whole blood and brain. The half-life 
in rat plasma was found to be 104±4 minutes, but less than 10 minutes in rat brain 
homogenate. Studies in the Aldrich laboratory using washings from striatal rat brain 
slices identified these metabolism sites (Figure 2-10) and followed the time course of 
the degradation over 30 minutes.95 MALDI-MS (matrix assisted laster 
desorption/ionization) was used to identify the metabolites. Table 2-3 lists the 
metabolites found at each time point along with the conditions - no inhibitors used, 
the aminopeptidase inhibitor bestatin, a carboxypeptidase inhibitor (CPase), and both 
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bestatin and the carboxypeptidase inhibitor. The inhibitors were used to prevent 
exopeptidase metabolism after cleavage by endopeptidases – this would allow for the 
identification of potential endopeptidase cleavage sites. In all but the last case the 
parent peptide (m/z 1535) disappears before 15 minutes.  Peptidase cleavage was 
found to occur at the N-termini of each arginine residue.96 
These sites show some similarities to the dynorphin metabolism sites 
discussed earlier, with cleavages occurring at mono- and dibasic sites. Similar to 
dynorphin A, arodyn is cleaved at Leu5-Arg6 and Arg6-Arg7 as well as at D-Ala8-Arg9 
(D-alanine substitution at the 8 position for isoleucine in Dyn A). In addition, a 
monobasic cleavage at Phe3-Arg4 is seen.95 
 
Ac-Phe-Phe-Phe-Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-NH2
m/z 441
m/z 1052
m/z 782
m/z 626
m/z 399  
Figure 2-10: Observed metabolites for arodyn following incubation with wash 
from  striatal rat brain slices.96 
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Table 2-3:Mass of arodyn metabolites following incubation with washing from in 
rat striata slices96 
Time 
(min) 
No Inhibitor Bestatin Carboxypeptidase 
Inhibitor 
Bestatin + 
Carboxypeptidase 
Inhibitor 
0  626, 782, 1535 441, 1535 441, 1535 441, 1535 
5  399, 441, 626, 
1535 
441, 626, 782, 
1052, 1535 
626, 782, 1535 626, 782, 1535 
15  399, 441, 626 441, 626, 782 441, 626 626, 782 
30  399, 441, 626 441, 626, 782 626 441, 626, 1535 
 
2.4.3 Strategies for Increasing Metabolic Stability 
 
Modifications to the structures of peptides can increase the biological stability 
of these compounds. These modifications can be targeted to the potential enzymatic 
cleavage sites (e.g. N-terminal protection for a peptide susceptible to aminopeptidase 
metabolism).  Some commonly used strategies are described below. 
2.4.3.1 Modifications to the N and C Termini 
 
Most peptides with free N- or C- termini are rapidly metabolized in plasma by 
exopeptidases.97 A few naturally occurring hormones, including thryotrphin releasing 
hormone (TRH) and melanocyte stimulating hormone (α-MSH), are stable in 
plasma.97 These peptides have modifications g at the N- and C- termini.  TRH has an 
α-pyroglutamyl at the N-terminus and α-prolineamide at the C-terminus that block 
attack from exopeptidases.97 α-MSH is protected at the N-terminus by acetylation and 
at the C-terminus by amidation.97   
Terminal protection of peptides is a commonly used technique in drug 
development. In one example, the pentapeptide thymopoietin exhibits an in vivo half-
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life of 1 min, while the double protected analog was observed to undergo no 
detectable degradation (for over 30 minutes).98  
Although protection of the N- and C-termini can stabilize peptides to 
metabolism by exopeptidases, this generally provides no protection against 
endopeptidase attack, as demonstrated with arodyn.  
2.4.3.2 Chirality Changes 
 
Naturally occurring peptides and proteins are made up of L-amino acids and 
exhibit high stereochemical specificity for interaction with enzymes. Thus, replacing 
L-amino acids with D-amino acids can improve stability. However, these alterations 
could change the preferred conformation of the peptide and could affect the biological 
activity.97  
2.4.3.3 Alkylation of the Amide Nitrogen 
 
Incorporation of a methyl group on an amide nitrogen is a commonly used 
strategy to increase peptide stability. N-Methylated analogs of endomorphin-2 show 
significantly improved stability while maintaining biological activity.99 However, the 
conformation of the peptide backbone can be altered as well as its hydrogen bonding 
capability.97 
2.4.3.4 Amide Bond Surrogate 
 
This approach replaces an amide bond in the peptide backbone with a group 
that is not susceptible to hydrolysis. Examples include replacing the amide bond with 
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a reduced amide bond (-CH2NH-) or with -CH2S-. These replacements would 
eliminate cleavage at the site of modification, but also affect the flexibility, 
conformation and hydrophobicity of the molecule.97 
2.4.3.5 Cyclization 
 
Cyclization of a peptide can reduce the peptide's conformational flexibility 
which may reduce interaction with the active site of a peptidase.97 Cyclization of 
[Met5]enkephalin was been reported to improve blood-brain barrier permeability as 
well as pharmacological and pharmacokinetic activity.100 A limitation for this 
approach is the feasibility of synthesizing the cyclic analog.97 
2.4.3.6 Side-chain Modification 
 
A simple approach is to replace the amino acids that are in the protease 
recognition site, with either natural or non-natural amino acids. Chlorination of the 
phenylalanine at the N-terminus of enkephalin prevents metabolism and improves 
blood-brain barrier permeability without loss of biological activity.100, 101 
2.5 Conclusions 
 
There is significant potential for the use of KOR antagonists for the treatment 
of cocaine abuse. KOR antagonism has been shown to prevent relapse of cocaine 
seeking behavior in mice subjected to stress. Small molecule KOR antagonists have 
exceptionally long-lasting pharmacological activity - up to several weeks after one 
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dose. This long-lasting activity could be problematic for the therapeutic development 
of these drugs. Therefore, we are investigating peptides as KOR antagonists in vivo. 
Peptides have been used as successful drugs. Although peptides often have 
shorter half-lives in vivo when compared to nonpeptide ligands, with appropriate 
modification they can have sufficiently long half-lives for use in vivo. The 
conditioned place preference tests showed promising results for arodyn in preventing 
stress-induced relapse of cocaine use.  More development of peptide KOR antagonists 
may result in an effective treatment for stress-induced addiction relapse. Based on in 
vivo studies, arodyn is a promising lead for further development. 
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3.1 Introduction 
 
Kappa opioid receptor (KOR) antagonists are increasingly gaining importance 
as potential new therapeutics for various disorders including drug addiction. KOR 
antagonists have shown antidepressant activity in the forced swim test in rats.1 They 
have shown antianxiolytic activity in rats.2 They can decrease the withdrawal signs in 
opioid addicted subjects (and therefore have potential application in the treatment of 
opioid addiction3, 4), and KOR antagonists have shown promise in the treatment of 
cocaine dependence by preventing stress induced relapse of drug seeking behavior.5, 6   
Arodyn (Ac-Phe-Phe-Phe-Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-NH2), a 
dynorphin A (Dyn A) analog, is a potent and selective antagonist of KOR.7 From the 
results in cocaine conditioned place preference assays in mice, arodyn shows 
potential in the treatment of stress-induced relapse of cocaine-seeking behavior.5 
Although arodyn has a  relatively long duration of action in vivo (1-3 days following 
introcerebroventricular administration) it has a very short half-life in rat brain 
homogenate and in rat brain slices; arodyn is rapidly metabolized with complete 
disappearance in 15 minutes.8 Analysis of the metabolism of arodyn in rat brain in 
our laboratory revealed several sites in the arodyn sequence that appear to be 
susceptible to proteolytic cleavage (Figure 3-1).  A cleavage between proline and 
lysine was identified after the results of these metabolism studies. 
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Ac-Phe-Phe-Phe-Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-NH2
 
Figure 3-1: Postulated cleavage sites for arodyn based on studies in striatal rat 
brain slice washings8   
Arodyn’s cleavage sites show some similarities to those known for Dyn A.  
Thimet-oligopeptidase (EC 3.4.24.15) is a metallo-endopeptidase that has been 
reported to be involved in the metabolism of a variety of peptides at the Leu-Arg 
bond, including the dynorphins.9 Endopeptidases selective for dibasic and monobasic 
sites in Dyn A have previously been reported.10-14 Dynorphin A converting enzyme 
(EC 3.4.22) can cleave at Arg6-Arg7 and Leu5-Arg6 as well as at other monobasic 
sites, and Ile8-Arg9 is cleaved by Dyn A processing enzyme.13 The metabolism of 
arodyn shows some similarities to Dyn A metabolism in that the cleavage sites are 
mono- or dibasic. Arodyn is cleaved at the N-terminus of every arginine – between 
residues 3-4 , 5-6, 6-7 and 8-9 peptide bonds in its sequence (a cleavage site at the N-
terminus of lysine, at the 10-11 peptide bond was identified later). 
 Metabolically stable analogs of arodyn are of interest in order to develop 
systemically active peptides that could eventually lead to a  therapeutically useful 
drug.   Since cleavage of arodyn was observed at the N-termini of the arginines, these 
sites were targeted for modification.  However, arodyn structure-activity relationship 
studies showed that the arginines are important residues for binding to KOR.15 Thus, 
the modifications should retain the side chain functionality of arginine that is 
important for receptor binding. Backbone modifications, such as using N-methyl 
amino acids and replacing peptide bonds with reduced amide bonds, retain side chain 
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functionalities while hindering cleavage by peptidases at those residues.16 With these 
considerations, we systematically replaced arginines in the arodyn sequence with N-
methylarginine. We also incorporated reduced amide bonds between positions 3-4, 5-
6, 6-7 and 8-9 in the sequence.  Extending the peptide sequence by additional amino 
acids may also affect the metabolism rate – dynorphin metabolism has been found to 
vary by the length of the sequence, with longer sequences often being metabolized 
more slowly.17 We extended the arodyn sequence with the addition of leucine in the 
12th position and lysine in the 13th position to give [Leu12]arodyn and 
[Leu12,Lys13]arodyn. These amino acids were chosen to mimic the Dyn A sequence. 
Here we describe the synthesis of these analogs and their metabolism in rat brain 
slices. Table 3-1 lists all of the analogs that were synthesized. 
Table 3-1: Synthesized arodyn analogs, listed by type of modification. 
Arodyn Analogs  
NMeArg Reduced Amide Bond Extended Other 
[NMeArg4] [Phe3Ψ(CH2NH)Arg4] [Leu12] [Lys6] 
[NMeArg6] [Leu5Ψ(CH2NH)Arg6] [Leu12,Lys13]  
[NMeArg7] [Lys6Ψ(CH2NH)Arg6]   
[NMeArg9] [D-Ala8Ψ(CH2NH)Arg9]   
3.2 Synthesis 
3.2.1 Extended Analogs and [Lys6]arodyn 
 
The extended analogs [Leu12]arodyn and [Leu12,Lys13]arodyn as well as the 
analog [Lys6]arodyn were synthesized using standard Fmoc (9-
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fluorenylmethoxycarbonyl) solid phase synthesis on the peptide amide linker 
poly(ethylene glycol)-polystyrene (PAL-PEG PS) resin, as described in the 
experimental section. The crude peptides were purified by preparative HPLC, and the 
pure fractions were combined after analysis of the fractions by analytical HPLC.  The 
purity of the combined fractions was confirmed by analytical HPLC in an 
acetonitrile/water (containing 0.1% TFA – trifluoroacetic acid) system and in a 
methanol/water (with 0.1% TFA) system (Table 3-2, the MS – mass sprectrometry – 
data is also listed).  
3.2.2 N-Methylarginine Analogs 
 
In order to best isolate the effects of individual modifications on the 
metabolism and fate of arodyn in rat brain slices, a single arginine was replaced with 
an N-methylarginine in each analog. All analogs were synthesized by Fmoc solid 
phase synthesis by a combination of automated and manual synthesis, using 
FmocNMeArg(Mtr) to incorporate NMeArg. Reaction times for coupling of the 
NMeArg and coupling the next amino acid in the sequence to NMeArg were 
somewhat longer than typical – 2-3 hours. Cleavage from the resin was done using 
modified Reagent K18 (90% TFA, 5% thioanisole, 2.5% phenol and 2.5% 3,6-dioxa-
1,8-octanedithiol)19, in order to remove the Mtr (4-methoxy-2,3,6-
trimethylbenzenesulfonyl) protecting group. The crude peptides were purified by 
preparative HPLC, and the pure fractions were combined after analysis of the 
fractions by analytical HPLC.  The purity of the combined fractions was confirmed 
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by analytical HPLC in an acetonitrile/water (0.1% TFA) system and in a 
methanol/water (0.1% TFA) system (Table 3-2).  
Table 3-2:  Analytical data for synthesized arodyn analogs. 
HPLC 
Rz(min)/purity(%) 
ESI-MS (m/z) Arodyn Analog 
System 1a System 2b Calculated Observed 
[Leu12] 25.69/100 32.04/100c [M+3H]3+=550.0 
[M+4H]4+=412.8 
[M+2TFA+2]2+=938.5 
[M+3H]3+=550.0 
[M+4H]4+=412.8 
[M+2TFA+2]2+=938.5 
[Leu12Lys13] 24.01/98.3 33.64/100 [M+3H]3+=592.7 
[M+4H]4+=444.8 
[M+3H]3+=593.0 
[M+4H]4+=444.8 
[NMeArg4] 24.88/100 40.79/100 [M+3H]3+=517.0 
[M+4H]4+= 388.0 
[M+2TFA+2]2+=888.5 
[M+3H]3+=517.0 
[M+4H]4+= 388.0 
[M+2TFA+2]2+=889.0 
[NMeArg6] 28.10/99 41.67/98.5 [M+3H]3+=517.0 
[M+4H]4+= 388.0 
[M+2TFA+2]2+=888.5 
[M+3H]3+=517.0 
[M+4H]4+=388.0 
[M+2TFA+2]2+=888.9 
[NMeArg7] 27.29/100 41.97/100 [M+2]2+=775.0 
[M+3H]3+=517.0 
[M+4H]4+= 388.0 
[M+2]2+=775.0 
[M+3H]3+=517.0 
[M+4H]4+= 388.0 
[NMeArg9] 27.22/100 26.03/98.4d [M+3H]3+=517.0 
[M+4H]4+= 388.0 
[M+2TFA+2]2+=888.5 
[M+3H]3+=517.0 
[M+4H]4+= 388.0 
[M+2TFA+2]2+=888.9 
[Phe3Ψ(CH2NH)Arg4] 23.74/99 37.69/99 [M+3H]3+=507.6 
[M+4H]4+= 381.0 
[M+2TFA+2]2+=875.0 
[M+3H]3+=508.0 
[M+4H]4+= 381.2 
[M+2TFA+2]2+=875.0 
[Leu5Ψ(CH2NH)Arg6] 21.99/99 39.19/100 [M+3H]3+=507.6 
[M+4H]4+= 381.0 
[M+2TFA+2]2+=875.0 
[M+3H]3+=507.6 
[M+4H]4+= 381.0 
[M+2TFA+2]2+=875.0 
[Lys6Ψ(CH2NH)Arg7] 22.62/99 37.14/100 [M+3H]3+=498.3 
[M+TFA+2]2+=804.0 
[M+3H]3+=498.3 
[M+TFA+2]2+=804.0 
[D-
Ala8Ψ(CH2NH)Arg9] 
21.97/99 39.81/100 [M+3H]3+=507.6 
[M+4H]4+= 381.0 
[M+2TFA+2]2+=875.0 
[M+3H]3+=507.6 
[M+4H]4+= 381.0 
[M+2TFA+2]2+=875.0 
[Lys6] 23.23/100 41.69/100 [M+3H]3+=503.0 [M+3H]3+=503.0 
a System 1: Solvent A = 0.1% TFA in water, solvent B = 0.1% TFA in acetonitrile.  
bSystem 2: Solvent A = 0.1% TFA in water, solvent B = 0.1% TFA in methanol. The gradient 
for both systems was 5-50%  solvent B, except where noted, over 45 min and the flow rate 
was 1mL/min. 
c 20% to 60%  solvent B over 45 min. 
d 20% to 70%  solvent B over 50 min. 
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3.2.3 Amides and Aldehydes 
 
The reduced amide bond analogs were synthesized using reductive amination 
with amino aldehydes. These aldehydes were prepared from the corresponding 
Weinreb amides. 
 The Weinreb amides were synthesized starting from Fmoc-protected amino 
acids as described in the experimental section and shown in Figure 3-2. The amino 
acids used were: Fmoc-Phe-OH, Fmoc-D-Ala-OH, Fmoc-Leu-OH and Fmoc-
Lys(Boc)-OH. Analytical HPLC and MS were used to confirm purity and identity of 
the Weinreb amides. The mass of the impurities in MS matched the mass of the 
expected by-products of PyBOP. The amides were then converted to aldehydes 
without purification.  
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Figure 3-2: Weinreb amide synthesis, followed by reduction to an aldehyde 
 
Fmoc-proteceted amino aldehydes were synthesized from the Weinreb amides 
(Figure 3-2) as described in the experimental section. The amino aldehydes Fmoc-
Phe-H, Fmoc-D-Ala-H, Fmoc-Leu-H and Fmoc-Lys(Boc)-H were successfully 
obtained. Proton NMR was used to confirm the presence of the aldehyde proton 
before proceeding with the reductive amination. The aldehydes were used within 18 
hours of preparation, without purification. 
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3.2.4 Reduced Amide Bond Analogs 
 
The reduced amide bond analogs were synthesized using the appropriate 
aldehydes. Lysine was substituted for arginine in position 6 in the analog that would 
have required an arginine aldehyde because Fmoc-protected lysine aldehydes were 
simpler to synthesize than arginine aldehydes. However, the lysine analog may show 
some differences in activity despite the similarity in charges. The cleavage of arodyn 
appears to occur on the N-terminal side of the arginine residues, and substitution of 
arginine by a lysine could alter the cleavage at the N-terminus of the lysine residue in 
addition to at the reduced amide bond. Therefore, [Lys6]arodyn was also synthesized 
for comparison in the metabolism studies of the effect of only the lysine substitution. 
[N-Me-Arg7]arodyn can also be used for comparison, as this analog has the same 
peptide bond modified as the Lys6  reduced amide analog but maintains arginine at 
position 6. 
The reductive amination of the deprotected peptide with the aldehyde and 
NaCNBH3 was performed for 3-5 hours. The reactions were followed by the 
ninhydrin test, which gave an orange/yellow color upon completion of the reaction. 
Aliquots taken at this step indicated no double alkylation occurred (confirmed by 
mass specrometry). The remaining amino acids in the peptide sequence were then 
introduced using standard procedures with PyBOP and HOBt as the coupling 
reagents.  
Acetylation of the completed peptide was first attempted using acetic 
anhydride. Mass spectra of the products revealed double acetylation, indicating that 
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the reduced amide bond was acetylated in addition to the amine terminus. Mass 
spectra of this, or earlier steps in the sequence, did not indicate any coupling of amino 
acids to the reduced amide bond site. A milder method of acetylation with 
acetylimidazole and DIEA (N,N-diisopropylethylamine) produced no double 
acetylation even under long reaction times (2-3 h). The crude peptides were purified 
by preparative HPLC, and the pure fractions were combined after analysis of the 
fractions by analytical HPLC.  The purity of the combined fractions was confirmed 
by analytical HPLC in an acetonitrile/water (0.1% TFA) system and in a 
methanol/water (0.1% TFA) system (Table 3-2).  
3.3 Binding Studies 
 
Preliminary binding studies are being carried out in Dr. Thomas Murray’s 
laboratory at Creighton University using [3H]diprenorphine as the radioligand for 
KOR. The initial results of these studies are summarized in Table 3-3. The extended 
analogs and N-methylarginine analogs showed roughly 4- to 5-fold lower KOR 
affinity than arodyn (Ki = 10 nM7). Studies on the binding of the reduced amide bond 
analogs are underway. All of these peptides will also be evaluated for affinity at the µ 
and δ opioid receptors to determine selectivity for KOR. 
Table 3-3: Binding to KOR of arodyn analogs. 
Arodyn Analog Ki ± SEM (nM) 
[Leu12] 52.7 ± 3.6 
[Leu12Lys13] 36.1 ± 2.7 
[NMeArg4] 50.1 ± 4.0 
[NMeArg6] 67.5 ± 4.7 
[NMeArg7] 66.1 ± 4.3 
[NMeArg9] 78.5 ± 5.9 
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3.4 Metabolism Studies 
Initially, five peptides were chosen for the metabolism studies. Both the 
reduced amide bond and N-methylarginine substitutions were expected to inhibit 
proteolytic cleavage at the site of modification.16 The reduced amide bond series of 
analogs was investigated in the initial studies.  In addition to the reduced amide bond 
series an extended analog, [Leu12,Lys13]arodyn, was also chosen for study. 
Striatal brain slices were used for our metabolism experiments. The slice 
washings are expected to be composed primarily of the extracellular enzyme fraction 
as opposed to rat brain homogenate, which is likely to contain both intra- and 
extracellular proteases. Arodyn is expected to be metabolized by extracellular 
enzymes in vivo; thus the rat brain slice experiments are expected to be more 
consistent with in vivo metabolism of these peptides. Reed et al. observed similar 
cleavage products for β-endorphin in vivo and in washes of striatal slices.20 
Extracellular enzymes have been implicated in the metabolism of Dyn A in a number 
of studies,14, 21 including in vivo experiments in rat striata.13 
 The peptides were incubated at 37 ºC with washings from striatal rat brain 
slices, with and without an aminopeptidase inhibitor (see experimental section for 
details).20 Inclusion of the aminopeptidase inhibitor bestatin enabled detection of the 
larger fragments of ardoyn analogs that, in the absence of the inhibitor, could undergo 
further degradation.  For example, cleavage between the Phe3-Arg4 residues of arodyn 
would leave an unprotected arginine at the N-terminus of one fragment, which could 
then be further cleaved by aminopeptidases. The presence of a carboxypeptidase 
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inhibitor in the experiment was found to have no effect on the types of metabolites 
found in earlier metabolism studies on the parent peptide arodyn.8 Aliquots, taken at 
3, 6, 10, 15, 30 and 60 minutes, were immediately placed on ice to stop further 
metabolism. Each aliquot was mixed with the matrix CHCA (α-cyano-4-
hydroxycinnamic acid) and then MALDI-MS (matrix-assisted laser desorption 
ionization mass spectrometry) was used to identify the metabolites. This method 
gives qualitative insight into the degradation of the peptides. Table 3-4 summarizes 
the major metabolites observed for each analog. The results are reported for the 
studies that were carried out in the presence of aminopeptidase inhibitor (the results 
with no inhibitor were similar and are given in Appendix 1).  Small metabolites (m/z 
< 700) are difficult to detect with this method due to background peaks (from the rat 
brain slice washings and the matrix) which show up in this region. In addition, more 
highly charged fragments are more easily detected – for arodyn and analogs the C-
terminal fragments are often detected while the N-terminal fragments are not. Figures 
showing the cleavages sites for each analog (and (M+H)+ values) are presented later 
in this chapter.  
The study of the metabolism of these peptides using rat brain slices using 
MALDI MS proved to be useful in identifying several metabolites of arodyn.8  Even 
though variability in the intensity was observed between time points for each analog, 
most of the analogs showed a consistent cleavage pattern predominantly involving the 
basic residues in the peptide sequences.  The modifications at the arginine residues 
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restricted cleavage at these residues.  Most peptides showed rapid proteolysis within 
the first 10 min of incubation with washings from striatal rat brain slices.  
Spectra peaks were considered to be significant with a signal to noise ratio of 
greater 25:1, with the exception of the blank where peaks were considered to be 
significant at a signal to noise ratio of greater than 10:1. Appendix 2 contains the 
spectra for the blank, [Leu12,Lys13]arodyn at 3, 6, 10, 15, 30 and 60 minutes as well as 
at 15 minutes incubation for [Phe3Ψ(CH2NH)Arg4]arodyn, [Leu5Ψ(CH2NH)Arg6], 
[Lys6Ψ(CH2NH)Arg7], [D-Ala8Ψ(CH2NH)Arg9], [NMeArg6]  and [NMeArg7]arodyn. 
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Table 3-4: Metabolites of arodyn analogs observed following incubation with 
washings from rat brain slices in the presence of bestatin.a 
Metabolites (m/z observed) Arodyn analog / 
(mol. weight)  3min 6min 10min 15min 30min 60min 
[Leu12,Lys13] / 
(1776) 
1777, 1293, 
1024 
1777, 1293, 
1165, 1052, 
1024,  924, 
867 
1777, 1293, 
1052, 1024, 
924, 867 
1777, 1293,  
1052, 1024, 
924,  867 
1777c,  
867 c 
No peaksb 
[Phe3Ψ(CH2NH)
Arg4] / (1520) 
1522, 1394, 
914, 757 
1522, 1394, 
914, 757 
1522, 1394, 
914, 757 
1522, 1394, 
914, 757 
1522, 
1394, 914, 
757 
914, 757 
[Leu5Ψ(CH2NH)
Arg6] / (1520) 
1522 1522, 1394 1522, 1394 1522, 1394, 
1141, 1038 
1522, 
1394, 
1141, 
1038  
1522, 1394, 
1141, 1038, 
911 
[Lys6Ψ(CH2NH)
Arg7] / (1491) 
1493, 1367, 
884 
1493, 1367, 
884 
1493, 1367, 
1010, 884 
1493,   
1367, 1010, 
884 
1493, 
1367, 
1010, 884 
1367, 1010, 
884 
[D-
Ala8Ψ(CH2NH)
Arg9] / (1520) 
1522, 1038 
 
1522, 1038 1522, 1038 1522, 1038 No peaksb No peaksb 
[NMeArg6] / 
(1547) 
1548, 1066 1548, 1066, 
939 
1548, 1066, 
939 
1548d, 
1066, 939 
1066, 939 939 
NMeArg7] / 
(1547) 
1548, 1066 1548, 1066, 
939 
1548, 1066, 
939 
1548, 1066, 
939 
1066, 939 939 
Arodyn  1535, 441 
(0 min) 
1535, 1052, 
782, 626, 
441 (5 min) 
ND 782, 636, 
441 
782, 626, 
441  
ND 
Blank 1450, 1411, 
1376, 772, 
757 
ND ND ND ND ND 
IInternal standard peaks: 1466, 1488 and 1504. 
bInternal standard was visible but no metabolite peaks were observed above the background. 
cPeak intensities very low (possibly difficult to read MALDI spot), these peaks were clear in non-
bestatin inhibited experiment at 30 min. 
d Signal/noise ratio is 17.57 
ND = not determined 
 
[Leu12,Lys13]arodyn was degraded into several metabolites. The parent 
peptide was still detectable up to 30 minutes (in contrast to arodyn which was not 
detected after 5 minutes). The cleavage sites are shown in Figure 3-3.  
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Ac-Phe-Phe-Phe-Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-Leu-Lys-NH2
m/z 1293
m/z 867
m/z 1165
m/z 1024
m/z 1052
m/z 924
 
Figure 3-3: Observed fragments for the extended analog [Leu12Lys13]arodyn. 
At 3 minutes cleavages between Phe3-Arg4 (m/z 1293) and Leu5-Arg6 (m/z 
1024) were detected. The 1293 fragment appeared to be cleaved further to yield 
smaller metabolites (m/z 1165 and 1052) at 6 min. Additional cleavages at this time 
point were between Arg6-Arg7 (m/z 867) and Pro10-Lys11 (m/z 1165).  Similar 
metabolites are seen at 10, 15 and 30 min. The parent peptide is still detectable after 
30 min. The observed fragments are listed in Table 3-5. 
Table 3-5: Relative intensity (% of internal standard) of detected metabolites of 
[Leu12,Lys13]arodyn. 
Time (min)  Fragment 
Mass 
(m/z) 
Sequence 
3 6 10 15 30 60 
1777 AcPhe-Phe-Phe-Arg-Leu-Arg-Arg-D-Ala-Arg-
Pro-Lys-Leu-Lys-NH2 
22 16 8 6 *  
1293 Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-Leu-Lys-
NH2 
12 39 19 9   
1165 Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-Leu  5     
1052 Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys  14 12 13   
1024 Arg-Arg-D-Ala-Arg-Pro-Lys-Leu-Lys-NH2 5 20 27 28   
924 Arg-Leu-Arg-Arg-D-Ala-Arg-Pro  9 8 9   
867 Arg-D-Ala-Arg-Pro-Lys-Leu-Lys-NH2  13 24 22 *  
*Peak intensities too low to read. 
There were no detectable metabolites or parent peptide seen after 30 minutes. 
The internal standard peak was still clear at 60 minutes, but no metabolites were seen 
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above the background. The only cleavage observed that did not occur at the N-
terminus of an arginine or lysine was between Lys11-Leu12.  However, this may be a 
secondary cleavage - the Leu12 may have been cleaved by a carboxypeptidase 
following cleavage of Leu12-Lys13.Thus, the extended analog [Leu12,Lys13]arodyn was 
cleaved at the N-termini of lysine and arginine residues and  had greater stability than 
arodyn. 
For [Phe3Ψ(CH2NH)Arg4]arodyn, the parent compound was detectable until 30 
minutes. Only three metabolites were detected, corresponding to cleavages between 
Leu5-Arg6 (m/z 757), Arg6-Arg7 (m/z 914) and Pro10-Lys11 (m/z 1394), all of which 
were detected as early as 3 minutes. Figure 3-4 shows the observed fragments and 
Table 3-6 lists these relative intensities of these fragments by the times at which they 
were detected. 
 
Figure 3-4: Observed fragments for [Phe3Ψ(CH2NH)Arg4]arodyn. 
Table 3-6: : Relative intensity (% of internal standard) of detected metabolites of 
[Phe3Ψ(CH2NH)Arg4]arodyn. 
Time (min) Fragment 
Mass 
(m/z) 
Sequence 
3 6 10 15 30 60 
1522 Ac-Phe-Phe-Phe−Ψ[CH2NH]-Arg-Leu-Arg-
Arg-D-Ala-Arg-Pro-Lys-NH2 
37 45 43 34 10  
1394 Ac-Phe-Phe-Phe−Ψ[CH2NH]-Arg-Leu-Arg-
Arg-D-Ala-Arg-Pro 
15 15 17 17 10  
914 Ac-Phe-Phe-Phe−Ψ[CH2NH]-Arg-Leu-Arg 14 12 17 20 21 35 
757 Ac-Phe-Phe-Phe−Ψ[CH2NH]-Arg-Leu 19 18 26 35 26 24 
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For [Leu5Ψ(CH2NH)Arg6]arodyn, parent compound was detected at 60 min - 
longer than any other analog and much longer than arodyn. This compound has four 
cleavage sites, each at the N-termini of arginine and lysine. The observed fragments 
are shown in Figure 3-5. The cleavage at Pro10-Lys11 was detected at 6 minutes and 
other cleavages (Arg6-Arg7 and D-Ala8-Arg9) were not detected until 15 minutes.  
Table 3-7: Relative intensity (% of the internal standard) of detected metabolites 
of [Leu5Ψ(CH2NH)Arg6]arodyn. 
Time (min) Fragment 
Mass 
(m/z) 
Sequence 
3 6 10 15 30 60 
1522 Ac-Phe-Phe-Phe-Arg-Leu- Ψ[CH2NH]-
Arg-Arg-D-Ala-Arg-Pro-Lys-NH2 
59 59 33 41 21 7 
1394 Ac-Phe-Phe-Phe-Arg-Leu- Ψ[CH2NH]-
Arg-Arg-D-Ala-Arg-Pro 
 18 10 30 29 19 
1141 Ac-Phe-Phe-Phe-Arg-Leu- Ψ[CH2NH]-
Arg-Arg-D-Ala 
   9 12 10 
1038 Arg-Leu- Ψ[CH2NH]-Arg-Arg-D-Ala-
Arg-Pro-Lys-NH2 
   12 13 4 
911 Ac-Phe-Phe-Phe-Arg-Leu- Ψ[CH2NH]-
Arg 
     7 
 
 
Figure 3-5: Observed fragments for [Leu5Ψ(CH2NH)Arg6]arodyn. 
 
Metabolism again occurred mainly at the N-termini of argnine and lysine 
residues for [Lys6Ψ(CH2NH)Arg7]arodyn, (see Figure 3-6). The parent compound 
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was seen after 30 minutes of incubation. There was no cleavage detected at the Leu5-
Lys6 bond.   Cleavages were seen as early as 3 minutes at Phe3-Arg4 and Pro10-Lys11 
(m/z 884, corresponding to cleavage of both the 3-4 and 10-11 bonds and m/z 1367). 
Cleavage of just the 3-4 bond (m/z 1010) was also detected at 10 minutes and later.  
Table 3-8 summarizes the fragments found and their relative intensities. 
Ac-Phe-Phe-Phe-Arg-Leu-Lys-![CH2NH]-Arg-D-Ala-Arg-Pro-Lys-NH2
m/z 1367
m/z 1010
m/z 884
 
Figure 3-6: Observed fragments for [Lys6Ψ(CH2NH)Arg7]arodyn. 
 
Table 3-8: Relative intensity (% of the internal standard) of detected metabolites 
of [Lys6Ψ(CH2NH)Arg7]arodyn. 
Time (min) Fragment 
Mass 
(m/z) 
Sequence 
3 6 10 15 30 60 
1493 Ac-Phe-Phe-Phe-Arg-Leu-Lys- 
Ψ[CH2NH]-Arg-D-Ala-Arg-Pro-Lys-
NH2 
57 54 29 32 11  
1367 Ac-Phe-Phe-Phe-Arg-Leu-Lys-
Ψ[CH2NH]-Arg-D-Ala-Arg-Pro 
4 8 10 17 11 11 
1010 Arg-Leu-Lys-Ψ[CH2NH]-Arg-D-Ala-
Arg-Pro-Lys-NH2 
  12 41 12 14 
884 Arg-Leu-Lys-Ψ[CH2NH]-Arg-D-Ala-
Arg-Pro 
7 9 13 12 4 4 
 
Only one metabolite was seen for [D-Ala8Ψ(CH2NH)Arg9]arodyn (Figure 3-7 
and Table 3-9), yet the parent compound only survived until 15 minutes. Although 
the internal standard was clearly visible at 30 and 60 minutes, no metabolites of the 
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arodyn analog could be seen above the background.  This could be due to further 
metabolism resulting in small metabolites that were not detectable using the MALDI. 
Table 3-9: Relative intensity (% of the internal standard) of detected metabolites 
of [D-Ala8Ψ(CH2NH)Arg9]arodyn. 
Time (min) Fragment 
Mass 
(m/z) 
Sequence 
3 6 10 15 30 60 
1522 Ac-Phe-Phe-Phe-Arg-Leu-Arg-Arg-D-
Ala-Ψ[CH2NH]-Arg-Pro-Lys-NH2 
30 11 9 4   
1038 Arg-Leu-Arg-Arg-D-Ala- Ψ[CH2NH]-
Arg-Pro-Lys-NH2 
8 6 5 4   
 
 
Figure 3-7: Observed fragments for [D-Ala8Ψ(CH2NH)Arg9]arodyn. 
 
The initial metabolism studies showed that the most stable peptide was 
[Leu5Ψ(CH2NH)Arg6]arodyn, which has the 5-6 bond stabilized as the reduced amide 
bond, where the parent peptide was detected after 60 minutes. The 5-6, i.e. Leu-Arg, 
cleavage is common among dynorphin derivatives and could be due to the enzyme 
thimet-oligopeptidase.9 This bond can also be cleaved by dynorphin converting 
enzyme.14  
[Lys6Ψ(CH2NH)Arg7]arodyn did not show the 5-6 bond cleavage. This could 
have been due to the substitution of lysine for arginine at residue 6. In order to 
investigate this, the metabolism of  [NMeArg7]arodyn was studied. This peptide also 
has a stabilized 6-7 bond, like [Lys6Ψ(CH2NH)Arg7]arodyn, but maintains an 
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arginine at the 6th position instead of a lysine. A 5-6 cleavage  in this analog would 
suggest that the presence of arginine could be important for the metabolism at this site 
and that replacement of arginine at this position by the basic amino acid lysine is 
deleterious to proteolysis of this bond (indicating enzyme selectivity for arginine over 
lysine). In addition, [NMeArg6]arodyn  was chosen to investigate whether 
stabilization of the 5-6 bond with an N-methyl group would result in a peptide as 
stable as the analog [Leu5Ψ(CH2NH)]Arg6arodyn. 
As shown in Table 3-4 [NMeArg6]arodyn  was not detected after 15 minutes, 
unlike [Leu5Ψ(CH2NH)Arg6]arodyn, which was observed for 60 minutes. Two major 
metabolites were seen for [NMeArg6]arodyn, one corresponding to a cleavage 
between Phe3-Arg4 (m/z 1066) and another between both Phe3-Arg4 and Pro10-Lys11 
(m/z 939). This is shown in Figure 3-8. The spectrum obtained following 15 minutes 
incubation is shown in Figure xxii in Appendix 2. Thus, the N-methylarginine analog 
had fewer metabolites (no cleavage of bonds 6-7 or 8-9) but faster metabolism of the 
parent peptide than the reduced amide bond analog. 
  
 
Figure 3-8: Observed fragments of [NMeArg6]arodyn. 
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Table 3-10: Relative intensity (% of the internal standard) of detected 
metabolites of [NMeArg6]arodyn. 
Time (min) Fragment 
Mass 
(m/z) 
Sequence 
3 6 10 15 30 60 
1548 Ac-Phe-Phe-Phe-Arg-Leu-NMeArg-Arg-
D-Ala-Arg-Pro-Lys-NH2 
25 40 26 50   
1066 Arg-Leu-NMeArg-Arg-D-Ala-Arg-Pro-
Lys-NH2 
30 144* 185* 366* 55 100 
939 Arg-Leu-NMeArg-Arg-D-Ala-Arg-Pro  64 112* 638* 184* 45 
 *Metabolite peak is larger than internal standard. 
[NMeArg7]arodyn had the same 6-7 bond stabilized as [Lys6ΨArg7]arodyn, 
but the parent [NMeArg7]arodyn was not observed after 15 minutes. The spectrum for 
the 15 minute incubation is shown in Figure xxiii in Appendix 2. The cleavages for 
the latter peptide were similar to those for [N-Me-Arg6]arodyn, as can be seen in 
Figure 3-9. No cleavage was seen at the 5-6 bond for [NMeArg7]arodyn. This would 
suggest that the lysine replacement in [Lys6Ψ(CH2NH)Arg7]arodyn did not affect the 
metabolism at this site. 
 
Figure 3-9: Observed fragments of [NMeArg7]Arodyn. 
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Table 3-11: Relative intensities (to the internal standard) of detected metabolites 
of [NMeArg7]arodyn. 
Time (min) Fragment 
Mass 
(m/z) 
Sequence 
3 6 10 15 30 60 
1548 Ac-Phe-Phe-Phe-Arg-Leu-Arg-NMeArg-
D-Ala-Arg-Pro-Lys-NH2 
24 13 46 25   
1066 Arg-Leu-Arg-NMeArg-D-Ala-Arg-Pro-
Lys-NH2 
13 15 26 16 9  
939 Arg-Leu-Arg-NMeArg-D-Ala-Arg-Pro  10 26 26 80 169* 
*Internal standard not largest peak. 
3.5 Summary 
 
Eleven new arodyn analogs were synthesized to find more metabolically 
stable peptides. Extended analogs and backbone modifications were the focus of these 
syntheses. A series of N-methylarginine analogs was prepared with single N-methyl-
arginine replacements for each arginine residue. A series of reduced amide bond 
analogs was also synthesized, each one containing a reduced amide bond at a known 
site of cleavage (at the N-terminus of each arginine residue). Also, two extended 
arodyn analogs were synthesized in order to investigate the effects of peptide length 
on proteolysis. 
One extended analog, the reduced amide bond series and two N-
methylarginine analogs were chosen for the metabolism studies. Cleavages for all of 
the analogs were generally found at the N-termini of basic residues (arginine and 
lysine), consistent with the previous results for arodyn. These results also have 
similarities to cleavage patterns for dynorphin13 in that cleavages are at mono- and 
dibasic sites. However, the enzymes responsible for cleaving these arodyn analogs 
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seem to show a selectivity for the N-terminus of basic residues, a selectivity which is 
not seen in dynorphin A metabolism.  
The Pro10-Lys11 cleavage was seen for every analog except [D-
Ala8Ψ(CH2NH)Arg9]arodyn. Both the N-methylarginine and reduced amide bond 
analogs showed extensive cleavage at the Pro10-Lys11 bond. This cleavage appears at 
the earliest time point (3 minutes) in 5 out of the 7 analogs.  Amidation of the C-
terminus and a nearby proline residue were not sufficient to prevent cleavage  at this 
site.  
  The Phe3-Arg4 bond was cleaved in all but one analog – the analog with 
stabilization at that site ([Phe3Ψ(CH2NH)Arg4]arodyn). This cleavage was seen at 3 
minutes for 5 out of 7 analogs. The parent [Phe3Ψ(CH2NH)Arg4]arodyn was detected 
until 30 minutes, longer than arodyn (which was not detectable by 15 minutes) but 
shorter than the longest lasting analog ([Leu5Ψ(CH2NH)Arg6]arodyn) tested in these 
studies.  
Other common cleavage sites included Arg6-Arg7, the cleavage products of 
which were observed for three of the analogs ([Leu12,Lys13]-, [Phe3Ψ(CH2NH)Arg4]-
and [Leu5Ψ(CH2NH)Arg6]). For the reduced amide analog with 6-7 bond stabilization 
([Lys6Ψ(CH2NH)Arg7]arodyn), the parent compound was detectable until 30 
minutes. Leu5-Arg6 was cleaved in only two of the analogs 
([Phe3Ψ(CH2NH)Arg4]arodyn and ([Leu12,Lys13]arodyn). The analog with the 5-6 
reduced amide bond, [Leu5Ψ(CH2NH)Arg6]arodyn, showed the greatest stability, 
with the parent compound detectable at 60 minutes. In earlier research on reduced 
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amide bond analogs of Dyn A, it was found that stabilization of the 5-6 bond with a 
reduced amide bond (to give the analog [Leu5Ψ(CH2NH)Arg6]Dyn A(1-11)NH2,) 
produced an analog that had a half-life of >500 minutes in mouse brain homogenate.22 
They also found this 5-6 bond was one of the most frequently cleaved bonds in Dyn 
A.22 Cleavage of D-Ala8-Arg9 was only seen for the analog 
[Leu5Ψ(CH2NH)Arg6]arodyn. 
Given the SAR of dynorphin A and the “message-address” concept,23 
cleavages in the “message” region of the peptide (residues 1-4) would produce 
metabolites lacking activity at opioid receptors. Cleavages in the rest of the peptide 
(the “address” region) may produce fragments with decreased KOR selectivity but 
that maintain activity at opioid receptors. Most of the cleavages for the analogs 
studied here occur in the address region, with one cleavage (of the 3-4 bond) that 
occurs late in the message sequence.  
Replacement of the 3-4, 5-6 or 6-7 peptide bonds with a reduced amide bond 
produced the most stable analogs – these compounds survived up to 30 to 60 minutes. 
However, corresponding N-methylarginine substitutions did not produce equally 
stable compounds. Neither [NMeArg6]arodyn nor [NMeArg7]arodyn survived beyond 
15 minutes in the metabolism studies. One reason for this unexpected observation 
could be due to the reduced amide bond imparting an additional positive charge to the 
peptide backbone, which may alter peptidase binding. The reduced amide bond could 
also alter the conformations of the peptides, which would change their binding to the 
peptidases. In either case, the reduced amide bond analogs could also have altered 
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receptor binding. Binding studies are in progress for these analogs to determine if 
KOR binding has been affected.  
3.6 Experimental 
3.6.1 Materials 
 
Standard Fmoc-protected amino acids were purchased from Bachem (King of 
Prussia, PA), Calbiochem-Novabiochem (San Diego, CA), Applied Biosystems 
(Foster City, CA), or Peptides International (Louisville, KY). The unnatural amino 
acid Fmoc-N-Me-Arg(Mtr)-OH was purchased from ChemImpex International 
(Wood Dale, IL). Fmoc-PAL-PEG-PS resin, DIEA and 7-azabenzotriazol-1-yloxy-
tris-(pyrrolidino)phosphonium hexafluorophosphate (PyAOP) were purchased from 
Applied Biosystems. 1-Hydroxy-7-azabenzotriazole (HOAt) was purchased from 
GenScript (Piscataway, NJ). 1-Hydroxybenzotriazole (HOBt) was purchased from 
Fisher Scientific.  Benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate (PyBOP) was purchased from Novabiochem. Lithium aluminum 
hydride, N,O-dimethylhydroxylamine hydrochloride, the MALDI matrix α-cyano-4-
hydroxycinnamic acid (CHCA) and other reagents were purchased from Sigma-
Aldrich (St. Lous, MO). All HPLC-grade solvents (AcOH, MeCN, diethyl ether, N,N-
dimethylformamide (DMF), dichloromethane (DCM), and MeOH) used for peptide 
synthesis or HPLC analysis were obtained from Fisher Scientific. TFA for HPLC 
analysis was also purchased from Fisher Scientific. 
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3.6.2 Synthesis of Weinreb Amides 
 
Synthesis of amides and aldehydes followed a procedure adapted from Meyer 
et al.24 Fmoc-Phe-OH (194 mg, 0.5 mmol) and PyBOP (286 mg, 0.55 mmol, 1.15 
equiv) were dissolved in DCM (5 mL). DIEA (0.3 mL, 1.5 mmol, 3 eqiuv) was added 
and the solution was stirred for several minutes. N,O-Dimethylhydroxylamine 
hydrochloride (59 mg, 0.6 mmol, 1.2 equiv) dissolved in DCM (5 mL) was added and 
the reaction was stirred for 1 h. The progress of the reaction was followed with TLC 
(1:1 EtOAc/hexane). DCM (10 mL) was added and the solution was washed three 
times with each of the following: 3N HCl, water, saturated NaHCO3 and brine. The 
organic layer was dried over MgSO4, filtered and then concentrated. A colorless oil 
was obtained. MS showed impurities that were possible PyBOP byproducts. The 
product was used without further purification.  ESI MS: 431.2 (M+H+), byproducts: 
258.2, 515.3, 537.3. The same byproduct peaks were present in all four different 
amides synthesized.  The MS results are consistent with known syntheses.25 
Other Weinreb amides were synthesized using the same procedure as above 
and the MS results are consistent with known syntheses: Fmoc-D-Ala-NOMe(Me) 
(MS 377.1, M+Na+)25, Fmoc-Leu-NOMe(Me) (397.2 M+H+)25 and Fmoc-Lys(Boc)-
NOMe(Me) (512.7 M+H+).26 
3.6.3 Synthesis of Aldehydes 
 
Fmoc-protected phenylalanine Weinreb amide (1590 mg, ~0.35 mmol) was 
dissolved in dry THF (4 mL) and the solution was cooled to 0 ºC under N2. LiAlH4 
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(1M solution in ether, 0.7 mL) was added dropwise and the progress of the reaction 
was followed by TLC (1:1 EtOAc:hexane). After 2 h, 1M KHSO4 solution (20 mL) 
and EtOAc (10 mL) was added at 0 ºC to quench the remaining LiAlH4. The reaction 
was stirred until it went clear, and then the layers were separated. The organic layer 
was washed twice with 1M KHSO4 and once with brine, then dried over Na2SO4, 
filtered and concentrated to give a yellow oil (91 mg, ~0.24 mmol, ~70%).  Proton 
NMR was used to confirm presence of the aldehyde (CDCl3 δ  9.65 (CHO)). This was 
consistant with known reports.27 The aldehyde was frozen and used within 18 h 
without further purification.  
Fmoc-D-Ala-H (CDCl3 δ  9.57 (CHO))28, Fmoc-Lys(Boc)-H(CDCl3 δ  9.58 
(CHO))26 and Fmoc-Leu-H (CDCl3 δ  9.58 (CHO))29 were synthesized following the 
same procedure as above.  
3.6.4 Peptide Synthesis: General Procedure 
Peptides were synthesized on the Fmoc-PAL-PEG-PS resin (200 mg, low-load 
resin), using the Fmoc synthetic strategy, as shown in Figure 3-10, generally with a 4-
fold excess of the Fmoc-protected amino acids.  The coupling reagents used were 
PyBOP, HOBt, and DIEA in a 1:1:2 ratio in 4-fold excess with respect to the resin 
substitution, using DMF (5 mL) as the solvent.  Generally coupling reaction times 
were 2 h (on an automated peptide synthesizer, CSBio) or until a negative ninhydrin 
test result was observed (on the CHOIR used for manual peptide synthesis30). The 
Fmoc group was removed from the amino acid with piperidine in DMF (20:80 v/v, 2 
x 20 min) followed by washing with DMF before coupling the next amino acid.  After 
   
 78 
the synthesis the peptides were cleaved from the resin for 2 h with Reagent B (88% 
TFA, 5% H2O, 5% phenol, and 2% TIPS – triisopropylsilane)31.  The peptides were 
filtered from the resin, and the filtrate was diluted with 10% aq acetic acid, extracted 
with ether, and then the ether was back extracted with 10% aq acetic acid.  The 
combined aqueous layers were lyophilized to dryness to give the crude peptides. 
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Figure 3-10: General scheme of peptide synthesis using the Fmoc strategy. 
 
3.6.4.1 HPLC and MS Analysis  
 
The peptides were purified using preparative reversed-phase high performance 
liquid chromatography (RP-HPLC) (Shimadzu SPD 10AVP HPLC system equipped 
   
 79 
with a Shimadzu SPD-10AVP detector) on a Vydac C18 column (10 µ, 300 Å, 22 x 
250 mm) equipped with a guard cartridge.  A linear gradient of 15-50% (or 10-45%) 
aqueous MeCN containing 0.1% TFA (20 mL/min) over 45-60 min was generally 
used, and elution was monitored at 214 nm.  Purity was evaluated using an analytical 
HPLC (Shimadzu SPD-10AVP equipped with a Shimadzu SPD-10AVP detector) and 
a Vydac C18 column (5 µ, 300 Ǻ, 5 x 50 mm) equipped with a guard cartridge.  The 
purity was verified using two orthogonal solvent systems - generally 5-50%  aqueous 
MeCN containing 0.1% TFA (1 mL/min) over 45 minutes and 5-50% aqueous MeOH 
containing 0.1% TFA (1 mL/min) over 45 minutes. Exceptions are noted under the 
synthesis of particular peptides. The eluents were monitored at 214 nm. 
The molecular weights of the peptides were determined by ESI-MS on Waters 
Q-TOF analyzer.  
3.6.5  Synthesis of [Leu12], [Leu12,Leu13] and [Lys6]arodyn 
 
These peptides were synthezised using the general procedure described above 
on the CSBio. Acetylation (using 1:1 acetic anhydride/DMF) was performed on the 
CSBio after the final Fmoc deprotection. 
After lyophilization, the crude peptides were purified via preparative HPLC. 
Pure compounds were analyzed with MS and HPLC, as described above. For 
[Leu12]arodyn the second system used was 20-60% aqueous MeOH (0.1% TFA) over 
45 min with a flow rate of 1 mL/min. Pure compounds isolated were [Leu12]arodyn: 
20 mg, [Leu12,Lys13]arodyn: 31 mg, and [Lys6]arodyn: 10 mg (all >98% purity in 
both systems).  
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3.6.6 NMeArg Analogs 
 
These peptides were synthesized primarily using the general peptide synthesis 
techniques described above, on the CSBio and on the CHOIR.  Fmoc-NMeArg(Mtr) 
(in a 2-fold excess) was coupled to the peptide using the coupling reagents PyBOP, 
HOBt and DIEA (2:2:4 fold excess relative to the resin substitution). The next amino 
acid in the sequence was coupled using PyAOP, HOAt and DIEA (4:4:8 fold excess). 
The peptides were cleaved from the resin by mixing with 5 mL of modified Reagent 
K18 (90% TFA, 5% thioanisole, 2.5% phenol and 2.5% 3,6-dioxa-1,8-octanedithiol)19 
overnight. A general extraction procedure was followed as described above.  
After lyophilization, the crude peptides were purified via preparative HPLC. 
For  [NMeArg9]arodyn, the second system used was aqueous MeOH (0.1% TFA) 
system with a gradient of 20-70% MeOH over 50 min and a flow rate of 1 mL/min. 
Pure compounds isolated were  [NMeArg4]arodyn: 12 mg, [NMeArg6]arodyn: 12 mg, 
[NMeArg7]arodyn: 9 mg and [NMeArg9]arodyn: 8 mg (each >98% purity in two 
systems). 
3.6.7 Reduced Amide Bond Analogs 
 
These peptides were assembled partly on the CSBio and partly on the CHOIR. 
The reduced amide bond was formed by first removing the Fmoc group from the 
peptide and then the aldehyde (0.5 mmol, 15 equiv) dissolved in DMF solution was 
added, followed by NaCNBH3  (20 mg, 0.3 mmol, 10 equiv) after 5 minutes.  The 
reaction was bubbled for 3-5 h. After the final Fmoc deprotection, acetylimidazole 
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(92 mg, 20 equiv) and DIEA (2 equiv) in DCM/DMF (1:2, 5 mL) were added. The 
reaction was then bubbled for 3 h. The peptide was cleaved from the resin by mixing 
with Reagent B (5 mL) for 3 h.  The extraction procedure was followed as described 
above. 
After lyophilization, the crude peptides were purified via preparative HPLC. 
Purity was confirmed with the HPLC solvent systems described earlier. Pure 
compounds isolated were [Phe3Ψ(CH2NH)Arg4]arodyn: 13 mg, 
[Leu5Ψ(CH2NH)Arg6]arodyn: 6 mg, [Lys6Ψ(CH2NH)Arg7]arodyn: 6 mg and [D-
Ala8Ψ(CH2NH)Arg9]arodyn: 10 mg (each >98% purity in two systems). 
3.6.8 Metabolism Studies 
 
 The procedure was followed as described by Reed et al.20 Rat brains were 
placed in a matrix and sliced; the striatum was dissected out from a 2 mm slice, while on 
ice, and then the striatal slices were placed on dry ice.  After warming to 4ºC on ice, the 
slices were washed once with phosphate buffered saline (PBS). Additional PBS (100 
µL) was added to the rat brain slice for 4 minutes. This solution was then divided into 
20 µL portions for each experiment. Two peptides per rat brain were analyzed (with 
no inhibitors and with bestatin) in addition to a blank control sample. These vials 
were kept at 4 ºC.  Bestatin, an aminopeptidase inhibitor, was added to one vial per 
peptide (1 µL of 10 mM solution for a final concentration of 500 µM). Peptide (2 µL 
of 100 µM solution for a final concentration of 10 µM) was added to each vial.  The 
vials were then warmed to 37 ºC. At each time point (3, 6, 10, 15, 30 and 60 min) 2 
   
 82 
µL was removed from each vial, cooled to 4 ºC and internal standard was added (10 
µM in MeCN, 2 µL, final concentration of 5 µM).  The internal standard was a 
known peptide ([Nα-benzyl-Tyr1,NMeArg7]Dyn A-(1-11)NH2, MW 1465)8. 
3.6.9 MALDI Analysis 
 
 The aliquots (1 µL), already mixed with internal standard as described above, 
were mixed with the matrix (1 µL), and the mixture was spotted onto the MALDI 
plate and dried before the analysis.  MALDI was performed in the positive ion mode. 
Instrument: Voyager-DE MALDI STR Biospectrometry Workstation, Applied 
Biosystems, Foster City. Matrix: α-cyano-4-hydroxycinnamic acid (CHCA). Internal 
standard: [Nα-benzyl-Tyr1,NMeArg7]Dyn A-(1-11)NH2. 
3.6.10 Binding Studies 
 
Radioligand binding assays were performed using cloned rat κ opioid 
receptors stably expressed on CHO cells.32 [3H]Diprenorphine was used as a 
radioligand in the assays. Nonspecific binding was determined in the presence of 10 
µM unlabeled Dyn A-(1-13)NH2. Binding assays were carried out under standard 
conditions. IC50 values were determined by nonlinear regression analysis to fit a 
logistic equation to the competition data using GraphPad Prism software (GraphPad 
Software Co., San Diego, CA). Ki values were calculated from the IC50 values by the 
Cheng and Prusoff equation,33 using KD value of 0.45 for [3H]diprenorphine. The 
results presented (Table 3-3) are the mean ± SEM from three separate assays. 
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4 Conclusions and Future Studies 
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4.1 Summary 
 
The objective of this research was to synthesize new arodyn analogs designed 
to have increased metabolic stability.   To meet this objective, 11 analogs were 
synthesized and 7 of these analogs were tested in metabolism studies.  Two extended 
analogs were prepared to investigate the effect of peptide length on the break down of 
arodyn. A series of N-methylarginine analogs and a series of reduced amide bond 
analogs were also synthesized. These backbone modifications preserved the side 
chain functionalities of arodyn, while stabilizing the bonds that had previously been 
identified as potential sites of cleavage.  One extended analog, the reduced amide 
bond series and two N-methyl arginine analogs were investigated in the initial 
metabolism studies.  
4.1.1 Metabolism 
 
Dynorphin A (Dyn A - H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-
Leu-Lys-Trp-Asp-Asn-Gln-OH) is the most studied endogenous ligand for the kappa 
opioid receptor (KOR). 
Dynorphin A is metabolized by both exopeptidases and endopeptidases. 
Endopeptidases selective for dibasic and monobasic sites in Dyn A have previously 
been reported.1-5 Thimet-oligopeptidase (E.C.3.4.24.15) is a metallo-endopeptidase 
that has been reported to be involved in the metabolism of a variety of peptides at the 
Leu-Arg bond, including the dynorphins.6 Dynorphin A converting enzyme (EC 
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3.4.22) can cleave at Leu5-Arg6 and Arg6-Arg7 as well as at other monobasic sites, 
and Ile8-Arg9 is cleaved by Dyn A processing enzyme.4 
Arodyn, (Ac[Phe1,2,3,Arg4,D-Ala8]Dyn A-(1-11) amide) was developed in the 
Aldrich laboratory as a dynorphin A analog. Arodyn exhibits high KOR selectivity 
and antagonist activity at KOR.7 In conditioned place preference assays in mice, 
arodyn showed promise as a treatment for stress-induced relapse of cocaine-seeking 
behavior.8 However, studies in rat brain slices showed that arodyn is rapidly 
metabolized, with complete disappearance of the parent compound in under 15 
minutes.9 These studies identified the possible sites of metabolism as at the N-termini 
of every arginine residue in the arodyn sequence, at internal monobasic and dibasic 
sites similar to the dynorphin A cleavage patterns. Arodyn is cleaved between 
residues 3-4 (a monobasic site next to an arginine), and, like Dyn A, at the 5-6, 6-7 
and 8-9 peptide bonds in its sequence. 
4.2 Conclusions 
 
 
Replacement of the 3-4, 5-6 or 6-7 peptide bonds with reduced amide bonds 
produced analogs with increased stability over arodyn – these compounds survived up 
to 30 to 60 minutes. N-Methylarginine stabilization of the 5-6 or 6-7 peptide bonds 
did not produce equally stable compounds. Neither [NMeArg6]arodyn nor 
[NMeArg7]arodyn survived beyond 15 minutes in the metabolism studies.  This could 
be due to a change in charge in the peptide backbone (the reduced amide bond adds a 
positive charge) or altered conformation of the peptide backbone from the reduced 
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amide bond – either of which could alter peptidase binding. Binding studies are in 
progress for all analogs to determine if KOR binding has been affected. N-
Methylarginine and extended analogs show somewhat reduced binding to KOR 
compared to arodyn’s binding, although these all still show affinity in the nanomolar 
range. 
These metabolism studies also identified the Pro10-Lys11 bond as a frequent 
site of cleavage. Following these studies, the arodyn metabolism data was reexamined 
and the Pro10-Lys11 bond was found to be cleaved.  The enzymes cleaving arodyn and 
these analogs appear to be selective for either arginine or lysine residues. 
4.3 Future Work 
 
Future work on this project includes completing the metabolism studies on the 
remaining analogs. The results from these, and the initial metabolism studies can be 
used in the design of future arodyn analogs. New arodyn analogs may be designed 
that include multiple sites of modification.  Stabilization of the 3-4 and 5-6 bonds 
with reduced amide bonds produced analogs with detectable parent compound at 30 
and 60 minutes, respectively. These sites also were frequently cleaved in the analogs 
studied, making these good targets for stabilization in new analogs. In addition, future 
work may include quantitative studies to determine half-lives for some of the analogs.  
Binding studies will be completed on the remaining reduced amide bond 
analogs. The results of these studies will help direct the design of future analogs.  
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Appendix 1  
 
Metabolites of arodyn analogs observed following inculcation in washings from rat 
brain slices with no inhibitors. 
 
Appendix 3 Metabolites Appendix 2 A
nalog / 
parent 
peptide  
Appendix 5 3
min 
Appendix 6 6
min 
Appendix 7 1
0min 
Appendix 8 1
5min 
Appendix 9 3
0min 
Appendix 10 6
0min 
Appendix 11 [
Leu12,Lys13] 
/ 1776 
Appendix 12 1
777, 
1293, 
1024, 
867 
Appendix 13 1
777, 
1293, 
1024, 
867 
Appendix 14 1
777, 
1293, 
1024,  
867 
Appendix 15 1
777, 
1024, 
867 
Appendix 16 8
67 
Appendix 17 N
o 
peaksa 
Appendix 18 [
Phe3Ψ(CH2
NH)Arg4] / 
1521 
Appendix 19 1
522, 
1394, 
914,  
757 
Appendix 20 1
522, 
1394, 
914, 
757 
Appendix 21 1
522, 
1394, 
914, 
757 
Appendix 22 1
522, 
1394, 
914, 
757 
Appendix 23 1
522, 
914, 
757 
Appendix 24 9
14, 
757 
Appendix 25 [
Leu5Ψ(CH2
NH)Arg6] / 
1521 
Appendix 26 1
522, 
1394, 
1038 
Appendix 27 1
522, 
1394, 
1038 
Appendix 28 1
522, 
1394, 
1141, 
1038 
Appendix 29 1
522, 
1394, 
1141 
Appendix 30 1
522, 
1394, 
1141 
Appendix 31 1
394, 
1141, 
911 
Appendix 32 [
Lys6Ψ(CH2
NH)Arg7] / 
1492 
Appendix 33 1
493 
Appendix 34 1
493, 
1367, 
884 
Appendix 35 1
493, 
1367, 
1010, 
884 
Appendix 36 1
493,   
1367, 
1010, 
884 
Appendix 37 1
367, 
1010, 
884 
Appendix 38 1
367, 
884 
Appendix 39 [
D-
Ala8Ψ(CH2
NH)Arg9] / 
1521 
Appendix 40 1
522 
Appendix 41  
Appendix 42 1
522 
Appendix 43 1
522 
Appendix 44 1
522 
Appendix 45 N
o 
peaks
a 
Appendix 46 N
o 
peaksa 
Appendix 47 [
NMeArg6] / 
1547 
Appendix 48 1
548, 
1066, 
939 
Appendix 49 1
548, 
1066, 
939 
Appendix 50 1
548, 
1066, 
939 
Appendix 51 1
548, 
939 
Appendix 52 1
548, 
1066, 
939 
Appendix 53 N
o 
peaksa 
Appendix 54 [
NMeArg7] / 
1547 
Appendix 55 1
548 
Appendix 56 1
548 
Appendix 57 1
548 
Appendix 58 1
548, 
1066, 
939 
Appendix 59 1
066, 
939 
Appendix 60 9
39 
bInternal standard was visible but no metabolite peaks were observed above the background. 
   
 92 
 
 
Appendix 2 
 
All figures are spectra from experiments with the aminopeptidase inhibitor bestatin. 
 
Figure xi: Blank spectrum of washings from rat brain slices (with internal 
standard). 
 
Figure xii: [Leu12,Lys13]aroydn metabolism in rat brain slice washing after 3 
minutes. 
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Figure xiii: [Leu12,Lys13]aroydn metabolism in rat brain slice washing after 6 
minutes. 
 
 
 
Figure xiv: [Leu12,Lys13]arodyn metabolism in rat brain slice washings, 10 
minutes. 
 
 
 
Figure xv: [Leu12,Lys13]aroydn metabolism in rat brain slice washing after 15 
minutes. 
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Figure xvi: [Leu12,Lys13]aroydn metabolism in rat brain slice washing after 30 
minutes. 
 
 
Figure xvii: [Leu12,Lys13]arodyn metabolism in rat brain slice washings, 60 
minutes (with bestatin). 
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Figure xviii: [Phe3Ψ(CH2NH)Arg4]arodyn metabolism in rat brain slice 
washings after 15 min. 
 
Figure xix: [Leu5Ψ(CH2NH)Arg6]arodyn metabolism in rat brain slice washings 
after 15 min. 
 
Figure xx: [Lys6Ψ(CH2NH)Arg7]arodyn metabolism in rat brain slice washings 
after 15 min. 
 
 
 
   
 96 
 
Figure xxi: [D-Ala8Ψ(CH2NH)Arg9]arodyn metabolism in rat brain slice 
washings after 15 min. 
 
Figure xxii: [NMeArg6]arodyn metabolism in rat brain slice washings after 15 
min. 
 
Figure xxiii: [NMeArg7]arodyn metabolism in rat brain slice washings after 15 
min.
 
